KRAS and familial pancreatic carcinoma: In spite of targeting RAS itself, a dual FT and geranylgeranyltransferase‐1 inhibitor named FGTI‐2734 can inhibit the growth of xenografts derived from four patients with pancreatic cancer with mutant KRAS (two G12D and two G12V) tumors.241